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Abstract: 
A series of novel B- and C-rings truncated deguelin derivatives have been designed 
and synthesized in the present study as heat shock protein 90 (Hsp90) inhibitors. The 
synthesized compounds exhibited micromolar antiproliferative potency toward a 
panel of human cancer cell lines. Their structure-activity relationships (SARs) were 
investigated in a systematic manner. Compound 21c was identified to have high 
Hsp90 binding potency (60 nM) and caused degradation of client proteins through 
ubiquitin proteasome system. Further biological studies showed that compound 21c 
induced a dose-dependent S and G2-phase cell cycle arrest on human breast cancer 
MCF-7 cells. Flow cytometry and Western blot analyses confirmed that compound 
21c caused apoptosis of MCF-7 cells. In addition, compound 21c showed much potent 
inhibition on the migration and invasion of MCF-7 cells. Taken together, these results 
suggest that 21c might be a promising lead compound for further development of 
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Hsp90 inhibitors. 
 
Keywords: Heat shock protein 90; deguelin; structure simplification; anticancer 
 
1. Introduction 
Heat shock protein 90 (Hsp90) is attracting increasing attention as a promising target 
for cancer treatment in recent years[1]. As a constitutively expressed chaperon, Hsp90 
plays a central role in assembly, folding, trafficking, and degradation processes of 
various client proteins involved in pathways of cell proliferation, angiogenesis, 
invasion and metastasis, and many of them are oncogenic proteins[2]. Additionally, 
Hsp90 is often overexpressed 2-10 fold higher in cancer cells than that in normal 
healthy cells[3]. Inhibition of Hsp90 by small molecules would result in degradation 
of the client proteins and suppress the growth and proliferation of cancers[4].Besides, 
targeting Hsp90 results in the regulation of multiple pathways simultaneously, and 
may also overcome the notorious cancer resistance issue due to its potential for 
combinatorial targeting of multiple oncogenic protein pathways[5]. These properties 
of Hsp90 make it an ideal and selective target for the treatment of cancers. 
Over the past decades, a number of Hsp90 inhibitors have been reported. The 
earlier Hsp90 inhibitors are developed from natural products, such as geldanamycin (1) 
and radicicol (2), which are good lead compounds for the development of Hsp90 
inhibitors[6]. 17-AAG (3), a semi-synthetic geldanamycin analogue designed to 
improve activity and reduce toxicity, once progressed to phase II clinical trials to treat 
patients with metastatic melanoma [7]. Then, various totally synthesized inhibitors of 
Hsp90 were developed with the aid of structure based drug design strategy[8]. To date, 
approximately more than 20 different compounds are in clinical studies, however, 
none Hsp90 inhibitors have been approved for use in clinical[9]. Several clinical trials 
of Hsp90 inhibitors have been discontinued due to effectiveness and toxicity. 
Consequently, there is an urgent need to develop new Hsp90 inhibitors. 
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Figure 1. Chemical structures of some Hsp90 inhibitors. 
 
Deguelin (4), a rotenoid isolated from the African plant Mundulea sericea 
(Leguminosae) and other plants, has been reported as a Hsp90 inhibitor with potent 
apoptotic and antiangiogenic effects on transformed cells and a variety of cancer 
cells[10]. Mechanism studies revealed that deguelin competes with ATP for binding 
with Hsp90, leading to the decrease of a series of Hsp90 client proteins, including p53, 
CDK4, MAPK-1/2, Akt, and HIF-1α[11]. Despite of promising anticancer activity of 
deguelin, the potential toxicity (Parkinson’s disease-like syndrome) of this compound 
in rats impended its direct application in clinic[12]. The complex structure of deguelin 
containing 5-fused rings designated as A-E rings (Figure 1), also raised a challenge 
for their chemical synthesis for structural modifications[13]. 
Tuning the structure of natural products plays an important role in transforming 
natural products to drugs[14]. For some natural products with structurally complex 
frameworks, truncating the structure may lead to simpler and synthetically more 
accessible fragment-like scaffolds. These core structures feature from NPs can also be 
used for further exploration of small druggable molecules[15]. Ring-truncated 
scaffolds of deguelin have been reported previously[16], however, the detailed 
structure-activity relationships of truncated deguelin derivatives have not been 
investigated intensively. In this study, twenty four structurally simpler truncated 
deguelin derivatives were designed as Hsp90 inhibitors by truncating B- and C-rings 
from deguelin and further modifying the A-, D- and E-rings (Figure 2). According to 
the previous reports, presence of the B- and C-rings of deguelin restricted the 
flexibility of deguelin, limiting the best conformation with which the deguelin 
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interacted with Hsp90[17]. Our molecular docking study also implied the 
conformational restriction of deguelin when docking into the active site of Hsp90 
(Figure 4B). Besides, the chemical construction of B- and C-rings of deguelin is the 
hardest step in total synthesis of this natural compound, truncating B- and C-rings of 
deguelin would be in favorable of chemical synthesis to develop its derivatives as 
Hsp90 inhibitors [18].  
According to the previous studies, the chromene skeleton (D and E rings) of deguelin 
was important for its activity, and the more extensive changes is inappropriate. 
Because the previous work implied that the methoxyl group was important to the 
activity of degelin. The modifications at R2 and carbonyl group were performed to 
explore the SAR of substitutes of different size and length. 
In this work, concise synthetic methodologies were further developed to prepare the 
novel B- and C-rings truncated deguelin derivatives based on our previous studies 
[19]. The antiproliferative activities of the synthesized compounds were evaluated and 
the mechanism of the most potent compound 21c was also investigated. 
 
Figure 2. Design strategy of truncated derivatives of deguelin. 
 
2. Results and discussion 
2.1. Chemistry 
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As shown in Scheme 1, the B- and C-rings truncated deguelin derivatives bearing 
phenolic hydroxy group at chromene moiety were synthesized via Friedel-Crafts 
acylation in three steps, which was much more concise than previously reported 
routes[12]. Briefly, acylates 7 were synthesized via Friedel-Crafts acylation using 
various substituted phenylacetic acids or phenylpropionic acid and resorcinol as 
starting materials with boron trifluoride diethyl etherate as the solvent. Chromene 
skeleton was constructed via selective propargylation of resorcinol 7 with 
3-chloro-3-methyl-1-butyne and a subsequent regioselective Claisen rearrangement. 
Thus, truncated deguelin derivatives 9a-f were obtained in three steps with acceptable 
total yields.  
 
Scheme 1. Synthesis of truncated deguelin derivatives 9a-fa 
 
aReagents and conditions: (a) BF3•Et2O, N2, 90oC, 80-90%; (b) 3-Chloro-3-methyl-1-butyne, KI, 
CuI, K2CO3, CH3CN, rt, 60-75%; (c) N,N-Dimethylaniline, 150 oC, 85-95%. 
 
With 9a-c as starting materials, target compounds bearing substitutions of different 
sizes (methyl, acetyl, and benzyl) at phenolic hydroxy group were obtained. As shown 
in Scheme 2, in the presence of 1 equiv of methyl iodide, the phenolic hydroxyl group 
of 9a-c was methylated preferentially to afford target compounds 10a, 10c, and 11, 
respectively. However, in the presence of more than 2 equiv of methyl iodide, the α 
position of carbonyl group was also methylated and gave compounds 10b and 10d. 
The double bond of 2H-chromene 11 was reduced in H2 atmosphere to provide 
chroman12 with a 95% yield. On the other hand, the carbonyl group of 11 was 
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converted to hydroxyl group using NaBH4 as the reductant, affording compound 13. 
The following elimination of hydroxyl at 60 oC region-selectively provided 
trans-alkenyl compound 14 in 90% yield. Acetylation of compound 9b with 
anhydride afforded compound 15, while benzylation of compound 9b with excessive 
benzyl bromide gave dibenzylated compound 16.  
 
Scheme 2. Synthesis of truncated deguelin derivatives 10-16a 
aReagents and conditions: (a) CH3I (1 equiv.), acetone, reflux, 80%; (b) H2, Pd/C, MeOH, 95%;(c) 
CH3I (2-3 equiv.), acetone, reflux, 80%; (d) NaBH4, MeOH, 0oC, 95%; (e) AcOH, 60oC,90%; (f) 
(CH3CO)2O, Et3N, DCM, rt, 90%; (g) BnBr, K2CO3, MeCN, reflux, 80%.  
 
Although the preparation of these truncated deguelin derivatives using 
Friedel-Crafts acylation is very effective, some target compounds could not be 
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obtained with this methodology due to the lack of commercially available 
polysubstituted phenylacetic acids. As shown in Scheme 3, key intermediate 
acylchromene 20 was firstly synthesized from dihydroxyacetophenone (17) using the 
Claisen rearrangement described above. Subsequently compound 20 reacted with 
various substituted bromobenzene to afford target compounds 21a-e in moderate 
yields. Synthesis of chroman 22 from chromene 21d was accomplished in 95% yield 
by reduction with H2 using Pd/C as a catalyst. The aldol condensation of ketone 19 
and benzaldehydes under the condition of NaH as base catalyst, THF as solvent 
provided target compounds 23a-b in moderate yield.    
 
Scheme 3. Synthesis of truncated deguelin derivatives 21-23a 
aReagents and conditions: (a) 3-Chloro-3-methyl-1-butyne, KI, CuI, K2CO3, CH3CN, rt, 60%; (b) 
N,N-Dimethylaniline,150oC, 95%; (c) CH3I, acetone, reflux, 80%; (d) Pd2(dba)3, DPE-phos, 
t-BuOK, THF, 70oC, 70%; (e) H2, Pd/C, MeOH, 95%; (f) NaH, THF, rt, 65%. 
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2.2. In vitro antiproliferative activities of truncated deguelin derivatives 
All compounds were firstly evaluated for their preliminary antiproliferative activities 
against human non-small cell lung cancer H1299 cells. Deguelin and Hsp90 inhibitor 
AT13387 were used as the positive controls. As shown in Table 1, the number and 
position of methoxy group in A-ring was vital to the antiproliferative effects of these 
compounds. Replacement of methoxy groups (9b) with chlorine atoms (9d) reduced 
the inhibition rate significantly at 10 µM. The inhibition rates of compounds 9a, 9c, 
9b, and 9e increased gradually along with the increase of methoxy groups at A-ring. 
Trimethoxybenzene seems to be the most favorable moiety for this region (9e, 21c, 
21d, and 22). Modifications on the linker between A- and D-ring was unfavorable for 
improving the activity of these derivatives, both increasing the length and reducing 
carbonyl resulted in analogues with less potent activity. By comparing the inhibition 
rates at 10 µM between 9c-e and 10c, 11, 21d, a conclusion could be draw that 
hydroxyl and methoxyl were all tolerated at D-ring, but large substitutions at D-ring 
decreased the activity significantly (15 and 16). In addition, reducing the double bond 
of E-ring resulted in increased activity (12 and 22).Furthermore, compounds 9e, 11, 
12, 21c-d and 22, which exhibited potent antiproliferative activities in preliminary 
screening, were selected for IC50 evaluations against H1299, MCF-7 and A549 cell 
lines. As shown in Table 2, all these compounds exhibited comparable 
antiproliferative activities to deguelin against three cancer cell lines. Among these 
compounds, 21c with a 2,4,5-trimethoxybenzene group was the most potent one with 
an IC50 value of 2.51 µM on MCF-7 cells.  
Table 1. Inhibition rates of compounds in H1299 cell line 
Compounds 
Inhibition rate (%)a 
0.1 µM 1.0 µM 10.0 µM 
9a 3.9±1.9 7.8±1.3 15.1±3.8 
9b 4.8±2.9 8.2±1.6 45.3±4.2 
9c 6.1±1.8 7.1±2.8 16.1±1.9 
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9d 8.3±2.7 9.1±2.3 11.5±2.3 
9e 9.7±2.4 19.7±1.7 49.0±6.5 
9f 3.6±0.9 8.5±0.8 30.1±4.8 
10a 5.6±1.2 9.3±1.3 11.3±1.8 
10b 4.5±1.8 6.5±1.2 15.5±2.0 
10c 3.6±0.4 7.3±1.8 10.6±1.5 
10d 7.1±1.0 10.8±1.3 13.3±1.9 
11 5.1±1.4 10.7±1.4 47.3±4.9 
12 7.2±1.5 12.4±1.4 49.3±5.3 
13 6.5±0.7 10.8±2.0 19.8±2.0 
14 5.2±2.0 8.6±1.8 14.4±1.7 
15 4.1±2.0 6.2±0.6 19.5±2.6 
16 2.1±1.2 2.5±0.8 9.9±0.8 
21a 7.1±1.9 10.2±2.8 40.1±4.7 
21b 4.7±1.2 10.4±1.2 38.2±4.3 
21c 15.3±1.8 40.3±7.8 72.1±8.0 
21d 9.6±1.7 27.4±2.6 58.3±4.8 
21e 3.5±0.7 6.5±1.0 28.1±3.9 
22 11.0±1.3 30.6±4.3 67.5±4.9 
23a 5.3±0.8 6.4±2.1 10.7±2.0 
23b 3.8±0.2 8.7±2.1 12.3±1.5 
Deguelin 9.9±1.6 28.5±2.7 65.3±7.9 
AT13387b 94.78±10.6 96.8±7.3 95.7±9.2 
aEach data represents mean±SD of three independent experiments 
bHsp90 inhibitor AT13387 was used as the positive control 
 
Table 2. Hsp90 binding activity and cell antiproliferative effects of representative 
compounds. 
Compounds IC50 (µM)a 
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H1299 MCF-7 A549 
Binding 
Hsp90 (FP)b 
9e 12.03±0.95 11.18±0.63 13.05±1.14 0.43 
11 11.83±0.96 6.88±0.72 6.00±0.53 0.09 
12 12.61±1.12 7.86±0.84 7.20±0.92 0.15 
21c 3.40±0.51  2.51±0.28  3.46±0.33  0.06 
21d 7.20±0.87 5.08±0.34 6.15±0.71 0.63 
22 5.72±0.67 5.22±0.48 5.33±0.57 0.28 
Deguelin 5.67±0.35 8.17±0.68 6.05±0.59 1.63 
AT13387c 0.37±0.06 0.29±0.08 0.44±0.03 0.02 
aMTT methods, cells were incubated with indicated compounds for 72h, the values are the means 
of three independent experiments; 
bBinding to N-terminal domain of Hsp90 was determined by a fluorescence polarization (FP) 
assay; 
cHsp90 inhibitor AT13387 was used as the positive control. 
 
 
Figure 3. Structure activity relationships of novel anti-tubulin compounds. 
 
2.3.Compound 21c directly bound to Hsp90 
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In order to confirm whether these compounds could bind to Hsp90, a fluorescence 
polarization (FP) assay was performed firstly. As shown in Table 2, all the tested 
target compounds (9e, 11, 12, 21c, 21d, and 22) showed appreciable binding affinity 
(0.06-0.43 µM) to recombinant human Hsp90α protein, which were relatively less 
potent to reference compound AT13387 (0.02 µM), but possessed much higher 
binding affinity to Hsp90 than deguelin (1.63 µM). Although compound 21c showed 
comparable affinity (0.06 µM) to Hsp90 than AT13387 (0.02 µM), the IC50 values of 
21c (2.51-3.46 µM) were much higher than that of AT13387 (0.29-0.44 µM) against 
three cancer cell lines. Besides, the structural similarity of compounds 11 and 21c 
resulted similar binding affinity to Hsp90 (0.09 µM for 11 and 0.06 µM for 21c), but 
the cytotoxicity of compound 11 was much lower than compound 21c, we presumed 
that the reason of this inconsistence might be complex system in a cell. 
 
Next, a monoclonal antibody that specifically bound to Hsp90 was used to 
immunoprecipitate Hsp90 and then detected whether 21c could interfere with this 
process. The results showed that 21c blocked the binding of Hsp90 with its antibody 
in a dose-dependent manner (data not shown). In order to understand the more precise 
binding mode of compound 21c with Hsp90, docking simulations were performed 
using the complex between the N-terminal domain of Hsp90 and 21c (PDB 
code:5J2X) as a template. The active site of the Hsp90 N-terminal was divided into 
S1, S2, and S3 three pockets, and deguelin only occupied S1 and S3 pockets (Figure 
4A). In addition, there was over contact between deguelin and S3 pocket due to 
conformational restriction (Figure 4B, deguelin shown in cyan). Truncating B- and C- 
rings of deguelin relieved the conformational restriction, as shown in Figure 4B, the 
most potent compound 21c (shown in pink) was inserted deeply into the S2 pocket 
and occupied S1, S2, and S3 pockets simultaneously. Interestingly, the SARs of these 
truncated deguelin derivatives summarized above can be well explained by the 
binding pattern taken by 21c in Figure 4D. One methoxyl at A-ring and carbonyl 
group formed hydrogen bonds to the residue LYS58, oriented the trimethoxybenzene 
moiety to occupy S2 pocket. The trimethoxybenzene group also formed a pi-cation 
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interaction with residue LYS58. Excessive size of substitutions at phenolic hydroxyl 
group of D-ring led to larger shifts, resulting in loss of the key hydrogen bond to the 
residue LYS58. Taken together, these results suggested that compound 21c could bind 
to Hsp90 directly, and this may provide useful information for further design of novel 
truncated deguelin Hsp90 inhibitors. 
 
Figure 4. Molecular modeling analysis of deguelin and compound 21c. (A) The 
predicted binding model of deguelin to Hsp90 (PDB code: 5J2X) catalytic site. The 
carbon atoms of deguelin are shown in cyan. The active site of the Hsp90 N-terminal 
is divided into S1, S2, and S3 three pockets, and deguelin occupies S1 and S3 pockets. 
(B) Docking poses of deguelin and 21c with Hsp90. The carbon atoms of deguelin are 
shown in cyan and the carbon atoms of 21c are shown in pink. Deguelin has over 
contact to S3 pocket due to conformational restriction. (C) Docking pose of 
compound 21c, key amino acid residues within the binding site are rendered in cyan 
capped stick. Red dashed lines are hydrogen bonding interactions. (D) The 2D 
interaction diagram of 21c. Hydrogen bonds were shown as violet lines and pi-cation 
interaction is indicated as magenta line. 
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2.4. Compound 21c induced the degradation of Hsp90 client proteins. 
Hsp90 inhibitors often cause rapid decline in client protein activities, and the 
degradation of client proteins through ubiquitin proteasome system[20]. Protein 
kinase B (PKB, also known as Akt) is the client protein of Hsp90, in order to 
investigate whether compound 21c could decrease the bind of Akt to Hsp90 and 
increase the ubiquitin-mediated degradation of Akt, co-immunoprecipitate (Co-IP) 
assay was performed. As shown in Figure 5A, the binding of Akt to Hsp90 could be 
clearly detected through Co-IP, however, in MCF-7 cells treated with 4 µM 21c, a 
decline in Hsp90-binded Akt was observed. Further detection of ubiquinated Akt in 
21c treated cells confirmed that 21c could bind to Hsp90 and mediate the degradation 
of Hsp90 client proteins through ubiquitin proteasome system (Figure 5B). Further 
Western blotting assay was performed to identify the inhibitory profile of 21c on 
Hsp90 client proteins. The results showed that 21c significantly downregulated the 
levels of Hsp90 clients p-mTOR, p-MAPK, p-AKT, HIF-1α, and survivin in a 
dose-dependent manner (Figure 5c). 
 
 
Figure 5. Compound 21c triggered degradation of multiple Hsp90 client proteins in a 
concentration dependent manner. (A) Inhibition of Hsp90 and Akt binding in vitro by 
compound 21c (4 µM); (B) Induced degradation of Akt protein by compound 21c (4 
µM); (C) Western-blot analysis of the expression levels of several client proteins of 
Hsp90 after incubation with 21c in MCF-7 cells.  
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
14 
 
2.5.Compound 21c inhibited cell growth by inducing S and G2-phase cell cycle 
arrest. 
To determine whether inhibition of cell proliferation was associated with cell cycle 
arrest, MCF-7 cells were treated with vehicle or various concentrations of 21c and the 
relative DNA content of cells were then analyzed by flow cytometry. The results 
showed that 21c-treated MCF-7 cells were arrested at the S and G2 phase. As shown 
in Figure 6, MCF-7 cells treated with 4 µM 21c for 48 h had 29.6% cells in G2 phase, 
as compared with 16.6% in the control. Conversely, the amount of cells at the G1 
phase significantly decreased from 60.6% (control) to 40.7% (treated with 4 µM 21c). 
 
 
Figure 6. Effects of compound 21c on cell cycle distribution of MCF-7 cells. Cells 
treated with DMSO or indicated concentrations of 21c for 36 h were analyzed for 
DNA content by flow cytometry.  
 
2.6. Induction of apoptosis by compound 21c 
In addition to cell cycle arrest, the overall cell growth inhibition induced by 21c could 
be caused by increase of apoptosis. Two separate assays were used to investigate the 
induction of apoptosis in MCF-7 cells by 21c. First, induction of apoptosis as a results 
of treatment of 21c was assessed by Hoechst 33258 staining. MCF-7 cells treated with 
vehicle or various concentrations of 21c for 36 h were stained with Hoechst 33258 
and the cell morphology was visualized by fluorescent microscopy. Characteristic 
features of apoptosis such as rounding of cells and nuclei, condensation and 
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peripherization of chromosome were clearly observed in MCF-7 cells after treatment 
with 21c (Figure 7).  
 
Figure 7. Hoechst 33258 staining of cells treated with 21c. Cell morphological 
alterations and nuclear changes associated with MCF-7 cells after incubation with 21c 
were assessed by staining with Hoechst 33258 and visualized by fluorescence 
microscopy, bars denote 50 µM. 
 
To further confirm whether 21c could induce apoptosis in MCF-7 cells, vehicle- or 
21c-incubated MCF-7 cells were stained with Annexin V and PI. As shown in Figure 
8A, incubation with 21c induced a concentration-dependent (0.5, 1.0, 2.0 and 4.0 µM) 
increase (from 13.6% to 71.8%) in both the early and late stage apoptosis of MCF-7 
cells.Besides, the expression of apoptotic proteins were detected to determine whether 
caspase-mediated apoptotic pathway was involved in 21c-treated cancer cells. 
Consistent with the results obtained from deguelin in previous reports, a marked 
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decrease in the level of Bcl-xL and increase in the level of cleaved caspase 3 were 
detected in the cells treated with 21c[21]. 
 
 
Figure 8. Effect of compound 21c on apoptosis in MCF-7 cells. (A) Cells were 
treated with DMSO or various concentrations of 21c for 36 h; (B) Histograms display 
the percentage of cell distribution. Data were represented as mean±SD of three 
independent experiments. *p<0.05, **p<0.01, and ***p<0.001 vs control group; (C) 
The expression of Bcl-xL and cleaved caspase-3 were analyzed by Western-blot 
analysis; (D) Histograms display the density ratios of Bcl-xL and cleaved caspase 3 to 
GAPDH. Data was represented as mean±SD of three independent experiments. 
*p<0.05, ***P<0.001, control compared with 21c treated cells. 
 
2.7. Inhibitory effects of 21c on migration and invasion of MCF-7 cells. 
Tumor invasion through extracellular matrix is an essential step in the tumor 
metastasis[22]. PI3K-Akt signaling has been shown to regulate cancer cell growth and 
invasion via increased motility and MMPs production[23]. In addition, deguelin has 
been reported to inhibit the invasion of cancer cells, thus, in the present study, effects 
of compound 21c on the migration and invasion of MCF-7 cells were examined[24]. 
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As shown in Figure 9A, the wound healing significantly decreased (indicative of 
decreased cell migration) in 21c-treated MCF-7 cells as compared to control cells, 
indicating that the migration of cells was significantly inhibited by 21c. Besides, the 
mean percentage value of the invaded cells through Matrigel-coated filters without 
test compound was 172.1±8.3 after 24 h incubation, compound 21c inhibited invasion 
of MCF-7 cells in a concentration dependent manner (Figure 9D). Although only a 
weak antiproliferative effect of 21c was observed at a concentration of 1 µM (Table 1), 
it showed much stronger inhibition on the invasion of MCF-7 cells, and the invaded 
cells were significantly decreased to 63.2±3.4 by 1 µM of 21c after 24 h incubation 
(Figure 9D). 
 
Figure 9. Compound 21c decreased the migration and invasion of breast cancer cells. 
(A) Wound healing assay of MCF-7 cells treated with various concentrations of 21c; 
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(B) Represent photomicrographs showing the invasive capability of MCF-7 cells was 
impaired by 21c in a dose-dependent manner; (C) The wounding area was quantified; 
(D) The number of migrating cells was determined by counting the stained cells and 
histogram. ***P<0.001, **P<0.01 compared with control group. 
 
3. Conclusion 
In summary, twenty four structurally simpler derivatives of natural product deguelin 
were obtained and identified as novel Hsp90 inhibitors by the optimization of 
chemical structure-truncating strategy. Some of the truncated deguelin derivatives 
displayed same or enhanced anti-proliferative efficacy on a panel of human cancer 
cell lines, indicating that simplification of B- and C-rings of deguelin retained its 
anticancer efficacy. The most potent compound 21c, was 3-fold more potent than 
parent molecule deguelin against MCF-7 cancer cells. Docking studies explained the 
high binding affinity of 21c to Hsp90 due to the relieved conformational restriction by 
truncating B- and C- rings of deguelin. Compound 21c was identified to have high 
Hsp90 binding potency (60 nM) and caused degradation of client proteins through 
ubiquitin proteasome system. In addition, the molecular mechanism study of 21c on 
the suppression of human breast cancer MCF-7 cell growth revealed that compound 
21c caused cancer cells arrest at G2/M phase of the cell cycle, and it significantly 
increased cell apoptosis, which was illustrated by chromatin condensation, 
externalization of phosphatidylserine and a marked decrease in the level of Bcl-xL 
and increase in the level of cleaved caspase 3. In additional, compound 21c showed 
much potent inhibition on the migration and invasion of MCF-7 cells. Collectively, 
our results demonstrated that the newly developed truncated deguelin derivative 21c 
possessed significant anticancer efficacy, and has the potential to be further 
development of Hsp90 inhibitors as anti-tumor agent. 
 
4. Experimental section 
4.1. General information 
All commercially available reagents were used without further purification. 
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Anhydrous solvents were dried through routine protocols. Flash column 
chromatography was carried out on 200-300 mesh silica gel (Qingdao Haiyang 
Chemical, China). Reactions were monitored by thin-layer chromatography (TLC) on 
0.25 mm silicagel plates (GF254) and visualized under UV light. 1H NMR and 13C 
NMR spectra were recorded with a Bruker AV-300 spectrometer (Bruker Company, 
Germany) in the indicated solvents (CDCl3 or DMSO-d6, TMS as internal standard): 
the values of the chemical shifts are expressed in δ values (ppm) and the coupling 
constants (J) in Hz. Low-and high-resolution mass spectrums (LRMS and HRMS) 
were measured on Finnigan MAT 95 spectrometer (Finnigan, Germany).  
 
4.2. Synthesis of target compounds 
4.2.1. 1-(2,4-Dihydroxyphenyl)-2-(3,4-dimethoxyphenyl)ethan-1-one (7b) 
3,4-Dimethoxyphenylacetic acid (1.0 g, 5.1 mmol, 1.0 equiv.) and resorcinol (561 mg, 
5.1 mmol, 1.0 equiv.) were added into 15 mL boron trifluoride ethyl etherate. The 
mixture was stirred at 90 ℃ for 1.5 h under the protection of nitrogen. 30 mL cold 
water containing 3.0 g sodium acetate was added into the reaction solution to 
precipitate the product. The mixture was filtered and the solid was purified by ethyl 
acetate to obtained 7b as a yellow solid (1.17 g, 80%). 1H NMR (300 MHz, DMSO-d6) 
δ 12.38 (s, 1H), 10.01 (s, 1H), 8.03 (d, J = 8.8 Hz, 1H), 6.91 (d, J = 2.0 Hz, 1H), 6.89 
(d, J = 8.2 Hz, 1H), 6.79 (dd, J = 8.2, 2.0 Hz, 1H), 6.75 (d, J = 2.4 Hz, 1H), 6.71 (dd, 
J = 8.9, 2.4 Hz, 1H), 4.25 (s, 2H), 3.72 (s, 3H), 3.72 (s, 3H); ESI-MS m/z 311.1 
[M+Na]+. 
 
4.2.2. 2-(3,4-Dimethoxyphenyl)-1-(2-hydroxy-4-((2-methylbut-3-yn-2-yl)oxy)phenyl) 
ethan-1-one (8b) 
Compound 7b (1.17 g, 4.06 mmol, 1.0 equiv.), 3-chloro-3-methyl-1-butyne (537 µL, 
4.87 mmol, 1.2 equiv.), copper iodide (77 mg, 0.4 mmol, 0.1 equiv.), potassium iodide 
(67 mg, 0.4 mmol, 0.1 equiv.) and potassium carbonate (673 mg, 4.87 mmol, 1.2 
equiv.) were added into 20 mL acetonitrile. The mixture was stirred at room 
temperature for 12 h. The solvent was removed at reduced pressure, and the residue 
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was treated with 10 mL water and extracted with ethyl acetate (3 × 30 mL). The 
combined organic phases were dried (Na2SO4), and the solvent was removed at 
reduced pressure. The crude residue was purified by column chromatography with 
petroleum/ethyl acetate (10:1) to give 8b as a white solid (0.72 g, 50%). 1H NMR 
(300 MHz, DMSO-d6) δ 12.38 (s, 1H), 8.03 (d, J = 8.8 Hz, 1H), 6.91 (d, J = 2.0 Hz, 
1H), 6.89 (d, J = 8.2 Hz, 1H), 6.79 (dd, J = 8.2, 2.0 Hz, 1H), 6.75 (d, J = 2.4 Hz, 1H), 
6.71 (dd, J = 8.8, 2.4 Hz, 1H), 4.25 (s, 2H), 3.83 (s, 1H), 3.72 (s, 3H), 3.72 (s, 3H), 
1.66 (s, 6H); ESI-MS m/z 355.2 [M+H]+. 
 
4.2.3. 
2-(3,4-Dimethoxyphenyl)-1-(5-hydroxy-2,2-dimethyl-2H-chromen-6-yl)ethan-1-one 
(9b) 
Compound 8b (0.72 g) was dissolved in 5 mL N,N-dimethylaniline, and the mixture 
was refluxed at 130 ℃ for 24 h. After the reaction was completed, 10 mL concentrated 
HCl was added and extracted with ethyl acetate (3 × 30 mL). The combined organic 
phases were dried (Na2SO4), and the solvent was removed at reduced pressure. The 
crude residue was purified by column chromatography with petroleum/ethylacetate 
(10:1) to give 9b as a white solid (0.68 g, 95%). 1H NMR (300 MHz, CDCl3) δ 12.92 
(s, 1H), 7.61 (d, J = 8.8 Hz, 1H), 6.76 (m, 3H), 6.66 (d, J = 10.1 Hz, 1H), 6.30 (d, J = 
8.8 Hz, 1H), 5.53 (d, J = 10.1 Hz, 1H), 4.10 (s, 2H), 3.82 (s, 6H), 1.41 (s, 6H); 13C 
NMR (75 MHz, CDCl3) δ 201.8, 159.6, 159.3, 148.5, 147.6, 130.9, 127.7, 126.3, 
121.0, 115.2, 112.5, 111.8, 110.8, 108.9, 107.9, 77.3, 55.4, 43.8, 27.9; HRESI-MS m/z 
calcd for C21H22O5 355.1540 [M+H]+, found 355.1557. 
 
4.2.4. 
1-(5-Hydroxy-2,2-dimethyl-2H-chromen-6-yl)-2-(4-methoxyphenyl)ethan-1-one (9c) 
Compound 9c was prepared as the same procedures of 9b with the commercially 
available 3,4-dimethoxyphenylacetic acid as the starting material. 1H NMR (300 MHz, 
CDCl3) δ 12.89 (s, 1H), 7.57 (d, J = 8.9 Hz, 1H), 7.14-7.06 (d, J = 8.1 Hz, 2H), 
6.84-6.76 (d, J = 8.1 Hz, 2H), 6.63 (d, J = 10.1 Hz, 1H), 6.26 (d, J = 8.9 Hz, 1H), 5.50 
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(d, J = 10.1 Hz, 1H), 4.06 (s, 2H), 3.72 (s, 3H), 1.37 (s, 6H); 13C NMR (75 MHz, 
CDCl3) δ 202.0, 159.6, 159.2, 158.1, 130.9, 129.9, 127.7, 125.9, 115.2, 113.7, 112.5, 
108.9, 107.9, 77.3, 54.8, 43.4, 27.85; HRESI-MS m/z calcd for C20H20O4, [M+H]+ 
325.1434, found 325.1488. 
 
4.2.5. 
2-(3,4-Dichlorophenyl)-1-(5-hydroxy-2,2-dimethyl-2H-chromen-6-yl)ethan-1-one 
(9d) 
Compound 9d was prepared as the same procedures of 9b with the commercially 
available 3,4-dichlorophenylacetic acid as the starting material. 1H NMR (300 MHz, 
CDCl3) δ 12.77 (s, 1H), 7.58 (d, J = 8.9 Hz, 1H), 7.42 (d, J = 8.2 Hz, 1H), 7.37 (d, J = 
2.1 Hz, 1H), 7.11 (dd, J = 8.2, 2.1 Hz, 1H), 6.71 (d, J = 10.1 Hz, 1H), 6.37 (d, J = 8.9 
Hz, 1H), 5.60 (d, J = 10.1 Hz, 1H), 4.17 (s, 2H), 1.47 (s, 6H); 13C NMR (75 MHz, 
CDCl3) δ 200.1, 159.6, 134.0, 132.2, 130.9, 130.5, 130.1, 128.4, 127.9, 115.1, 112.3, 
109.0, 108.3, 77.5, 43.0, 27.9; HRESI-MS m/z calcd for C19H16Cl2O3 363.0549 
[M+H]+, found 363.0590. 
 
4.2.6. 
1-(5-Hydroxy-2,2-dimethyl-2H-chromen-6-yl)-2-(3,4,5-trimethoxyphenyl)ethan-1-on
e (9e) 
Compound 9e was prepared as the same procedures of 9b with the commercially 
available 3,4,5-trimethoxyphenylacetic acid as the starting material. 1H NMR (300 
MHz, CDCl3) δ 12.92 (s, 1H), 7.62 (d, J = 8.8 Hz, 1H), 6.68 (d, J = 10.2 Hz, 1H), 
6.45 (s, 2H), 6.32 (d, J = 8.8 Hz, 1H), 5.59 (d, J = 10.2 Hz, 1H), 4.11 (s, 2H), 3.82 (s, 
9H), 1.43 (s, 6H); 13C NMR (75 MHz, CDCl3) δ 201.5, 159.6, 159.4, 152.8, 130.8, 
129.5, 129.1, 127.8, 115.1, 112.5, 108.8, 108.0, 106.2, 105.9, 77.4, 60.3, 55.6, 44.4, 
27.8; HRESI-MS m/z calcd for C22H24O6 385.1646 [M+H]+, found 385.1679. 
 
4.2.7. 
3-(3,4-Dimethoxyphenyl)-1-(5-hydroxy-2,2-dimethyl-2H-chromen-6-yl)propan-1-one 
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(9f) 
Compound 9f was prepared as the same procedures of 9b with the commercially 
available 3,4-dimethoxyhydrocinnamic acid as the starting material. 1H NMR (300 
MHz, CDCl3) δ 13.06 (s, 1H), 7.52 (d, J = 8.9 Hz, 1H), 6.78 (m, 3H), 6.72 (d, J = 
10.1 Hz, 1H), 6.31 (d, J = 8.8 Hz, 1H), 5.58 (d, J = 10.1 Hz, 1H), 3.87 (d, J = 3.8 Hz, 
6H), 3.20 (t, J = 7.5 Hz, 2H), 2.99 (t, J = 7.5 Hz, 2H), 1.45 (s, 6H); 13C NMR (75 
MHz, CDCl3) δ 203.3, 159.2, 159.1, 148.4, 147.0, 133.0, 130.3, 127.7, 119.6, 115.3, 
112.9, 111.2, 110.8, 108.8, 107.8, 77.2, 55.4, 55.3, 39.3, 29.6, 27.8; HRESI-MS m/z 
calcd for C22H24O5 369.1722 [M+H]+, found 369.1739.  
 
4.2.8. 
2-(3,4-Dimethoxyphenyl)-1-(5-methoxy-2,2-dimethyl-2H-chromen-6-yl)ethan-1-one 
(11) 
Compound 9b (500 mg, 1.41 mmol, 1.0 equiv.), methyl iodide (131 µL, 2.12 mmol, 
1.5 equiv.), and potassium carbonate (292 mg, 2.12 mmol, 1.5 equiv.) were dissolved 
in acetone (20 mL).The mixture was refluxed for 12 h. After the reaction was 
completed, allow it to cool to room temperature. The solvent was removed at reduced 
pressure, and the residue was treated with 10 mL water and extracted with ethyl 
acetate (3 × 30 mL). The combined organic phases were dried (Na2SO4), and the 
solvent was removed at reduced pressure. The crude residue was purified by column 
chromatography with petroleum/ethyl acetate (8:1) to give 11 as a white solid (0.36 g, 
70%). 1H NMR (300 MHz, CDCl3) δ 7.41 (d, J = 8.6 Hz, 1H), 6.70 (s, 3H), 6.51 (m, 
2H), 5.59 (d, J = 10.0 Hz, 1H), 4.11 (s, 2H), 3.75 (s, 6H), 3.68 (s, 3H), 1.35 (s, 6H); 
13C NMR (75 MHz, CDCl3) δ 198.2, 157.3, 155.9, 148.3, 147.3, 130.7, 130.1, 127.1, 
124.3, 121.2, 116.0, 114.3, 112.2, 112.2, 110.7, 76.4, 62.8, 55.3, 55.3, 47.7, 27.5; 
HRESI-MS m/z calcd for C22H24O5 369.1697 [M+H]+, found 369.1712. 
 
4.2.9. 1-(5-Methoxy-2,2-dimethyl-2H-chromen-6-yl)-2-phenylethan-1-one (10a) 
Compound 10a was prepared as the same procedures of 11 with the commercially 
available phenylacetic acid as the starting material. 1H NMR (300 MHz, CDCl3) δ 
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7.56 (d, J = 8.6 Hz, 1H), 7.28 (m, 5H), 6.63 (d, J = 10 Hz, 1H), 6.60 (d, J = 8.7 Hz, 
1H), 5.70 (d, J = 10.0 Hz, 1H), 4.29 (s, 2H), 3.78 (s, 3H), 1.47 (s, 6H); 13C NMR (75 
MHz, CDCl3) δ 201.7, 156.7, 155.4, 140.9, 130.4, 130.0, 128.1, 127.5, 126.2, 124.9, 
116.1, 114.4, 111.9, 76.3, 62.8, 50.0, 27.6, 27.5; HRESI-MS m/z calcd for C20H20O3 
309.1485 [M+H]+, found 309.1505. 
 
4.2.10. 1-(5-Methoxy-2,2-dimethyl-2H-chromen-6-yl)-2-phenylpropan-1-one (10b) 
Compound 10b was prepared as the same procedures of 11 with the commercially 
available phenylacetic acid and 3 equivalent of methyl iodide as the starting material. 
1H NMR (300 MHz, CDCl3) δ 7.38 (d, J = 8.6 Hz, 1H), 7.28 (m, 4H), 7.20 (d, J = 8.7 
Hz, 1H), 6.60 (d, J = 10 Hz, 1H), 6.54 (d, J = 8.7 Hz, 1H), 5.66 (d, J = 10.0 Hz, 1H), 
4.73 (d, J = 6.9 Hz, 1H), 3.68 (s, 3H), 1.54 (d, J = 6.9 Hz, 3H), 1.43 (s, 6H); 13C NMR 
(75 MHz, CDCl3) δ 201.7, 156.7, 155.4, 140.9, 130.4, 130.0, 128.1, 127.5, 126.2, 
124.9, 116.1, 114.4, 111.9, 76.3, 62.8, 50.0, 27.6, 27.5, 18.8; HRESI-MS m/z calcd for 
C21H22O3 323.1642 [M+H]+, found 323.1678.  
 
4.2.11. 
1-(5-Methoxy-2,2-dimethyl-2H-chromen-6-yl)-2-(4-methoxyphenyl)ethan-1-one 
(10c) 
Compound 10c was prepared as the same procedures of 11 with the commercially 
available 3,4-dimethoxyphenylacetic acid as the starting material. 1H NMR (300 MHz, 
CDCl3) δ 7.47 (d, J = 8.6 Hz, 1H), 7.13 (d, J = 8.7 Hz, 2H), 6.81 (d, J = 8.7 Hz, 2H), 
6.56 (m, 2H), 5.65 (d, J = 10.0 Hz, 1H), 4.16 (s, 2H), 3.74 (s, 3H), 3.73 (s, 3H), 1.41 
(s, 6H); 13C NMR (75 MHz, CDCl3) δ 202.0, 157.8, 156.6, 155.3, 132.9, 130.4, 130.0, 
128.5, 124.9, 116.1, 114.3, 113.5, 111.9, 76.2, 62.9, 54.7, 49.1, 27.5; HRESI-MS m/z 
calcd for C21H22O4 339.1591 [M+H]+, found 339.1612. 
 
4.2.12. 
1-(5-Methoxy-2,2-dimethyl-2H-chromen-6-yl)-2-(4-methoxyphenyl)propan-1-one 
(10d) 
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Compound 10d was prepared as the same procedures of 11 with the commercially 
available 4-methoxyphenylacetic acid as the starting material. 1H NMR (300 MHz, 
CDCl3) δ 7.28 (d, J = 8.6 Hz, 1H), 7.15 (d, J = 8.2 Hz, 2H), 6.76 (d, J = 8.2 Hz, 2H), 
6.50 (d, J = 8.6 Hz, 1H), 6.49 (d, J = 10.0 Hz, 1H), 5.61 (d, J = 10.0 Hz, 1H), 4.60 (d, 
J = 6.9 Hz, 1H), 3.71 (s, 3H), 3.63 (s, 3H), 1.45 (d, J = 6.9 Hz, 3H), 1.38 (s, 6H); 13C 
NMR (75 MHz, CDCl3) δ 202.0, 157.8, 156.6, 155.3, 132.9, 130.4, 130.0, 128.5, 
124.9, 116.1, 114.3, 113.5, 111.9, 76.2, 62.9, 54.7, 49.1, 27.5, 18.7; HRESI-MS m/z 
calcd for C22H24O4 353.1747 [M+H]+, found 353.1781. 
 
4.2.13. 
2-(3,4-Dimethoxyphenyl)-1-(5-methoxy-2,2-dimethylchroman-6-yl)ethan-1-one (12) 
To a solution of compound 11 (100 mg) in methanol (10 mL) was added catalytic 
amount of 10% Pd/C. The mixture was reacted under the atmosphere of hydrogen at 
room temperature for 12 h. After the reaction was completed, the mixture was filtrated 
to remove Pd/C and the solvent was removed at reduced pressure to obtained 12 as a 
white solid (95 mg, 95%). 1H NMR (300 MHz, CDCl3) δ 7.47 (d, J = 8.7 Hz, 1H), 
6.77 (s, 3H), 6.56 (d, J = 8.7 Hz, 1H), 4.17 (s, 2H), 3.81 (s, 6H), 3.73 (s, 3H), 2.74 (t, 
J = 6.6 Hz, 2H), 1.77 (t, J = 6.6 Hz, 2H), 1.31 (s, 6H); 13C NMR (75 MHz, CDCl3) δ 
198.4, 158.7, 158.4, 148.6, 147.2, 128.9, 127.2, 123.1, 121.2, 114.7, 112.8, 112.2, 
110.7, 74.9, 61.3, 55.3 (two carbons), 47.5, 31.5, 26.2, 16.8; HRESI-MS m/z calcd for 
C22H26O5 371.1853 [M+H]+, found 371.1889. 
 
4.2.14. 
2-(3,4-Dimethoxyphenyl)-1-(5-methoxy-2,2-dimethyl-2H-chromen-6-yl)ethan-1-ol 
(13) 
To a solution of compound 11 (1.0 g, 2.71 mmol, 1.0 equiv.) in methanol (20 mL) was 
added sodium borohydride (205 mg, 5.43 mmol, 2.0 equiv.) at 0 oC. The reaction 
mixture was stirred at this temperature for 1 h. After the reaction was completed, the 
reaction was quenched with saturated ammonium chloride solution. The reaction 
mixture was treated with 10 mL water and extracted with ethyl acetate (3 × 30 mL). 
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The combined organic phases were dried (Na2SO4), and the solvent was removed at 
reduced pressure. The crude residue was purified by column chromatography with 
petroleum/ethyl acetate (6:1) to give 13 as a white solid (0.95 g, 95%).1H NMR (300 
MHz, CDCl3) δ 7.13 (d, J = 8.4 Hz, 1H), 6.72 (s, 2H), 6.61 (s, 1H), 6.56 (d, J = 8.4 
Hz, 1H), 6.48 (d, J = 9.9 Hz, 1H), 5.59 (d, J = 9.9 Hz, 1H), 5.06-4.97 (m, 1H), 3.78 (s, 
3H), 3.75 (s, 3H), 3.59 (s, 3H), 2.99-2.80 (m, 2H), 2.24 (s, 1H), 1.37 (s, 6H); 13C 
NMR (75 MHz, CDCl3) δ 152.9, 148.2, 147.1, 130.6, 129.9, 128.0, 126.4, 121.0, 
116.6, 113.9, 112.3, 112.2, 110.6, 75.2, 69.1, 62.1, 55.4, 55.2, 43.9, 27.2, 27.1; 
HRESI-MS m/z calcd for C22H26O5 371.1853 [M+H]+, found 371.1877. 
 
4.2.15. (E)-6-(3,4-Dimethoxystyryl)-5-methoxy-2,2-dimethyl-2H-chromene (14) 
To a solution of acetic acid was added compound 13 (500 mg), and the mixture was 
heated to 60 oC. After the reaction was completed, saturated sodium bicarbonate 
solution was added to quench to the reaction. The reaction mixture was treated with 
10 mL water and extracted with ethyl acetate (3 × 30 mL). The combined organic 
phases were dried (Na2SO4), and the solvent was removed at reduced pressure. The 
crude residue was purified by column chromatography with petroleum/ethyl acetate 
(6:1) to give 14 as a white solid (0.45 g, 90%). 1H NMR (300 MHz, CDCl3) δ 7.39 (d, 
J = 8.6 Hz, 1H), 7.18 (d, J = 16.4 Hz, 1H), 7.07 (m, 2H), 6.96 (d, J = 16.4 Hz, 1H), 
6.87 (d, J = 8.6 Hz, 1H), 6.64 (m, 2H), 5.67 (d, J = 10.0 Hz, 1H), 3.96 (s, 3H), 3.91 (s, 
3H), 3.79 (s, 3H), 1.46 (s, 6H); 13C NMR (75 MHz, CDCl3) δ 153.3, 153.0, 148.6, 
148.1, 130.7, 130.0, 126.9, 125.7, 122.8, 120.7, 119.0, 116.5, 114.3, 112.4, 110.8, 
108.3, 75.6, 61.9, 55.5, 55.4, 27.4; HRESI-MS m/z calcd for C22H24O4, 353.1747 
[M+H]+, found 353.1759. 
 
4.2.16. 6-(2-(3,4-Dimethoxyphenyl)acetyl)-2,2-dimethyl-2H-chromen-5-yl acetate 
(15) 
To a solution of compound 9b (100 mg, 0.28 mmol, 1.0 equiv.) in dichloromethane 
(15 mL) was added triethylamine (78 µL, 0.56 mmol, 2.0 equiv.) and acetic anhydride 
(80 µL, 0.84 mmol, 3.0 equiv.). The mixture was stirred at room temperature for 10 h. 
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After the reaction was completed, saturated sodium bicarbonate solution was added to 
quench the reaction. The reaction mixture was treated with 10 mL water and extracted 
with ethyl acetate (3 × 30 mL). The combined organic phases were dried (Na2SO4), 
and the solvent was removed at reduced pressure. The crude residue was purified by 
column chromatography with petroleum/ethyl acetate (6:1) to give 15 as a white solid 
(100 mg, 90%). 1H NMR (300 MHz, CDCl3) δ 7.71 (d, J = 8.6 Hz, 1H), 6.83 (d, J = 
8.0 Hz, 1H), 6.75 (m, 2H), 6.70 (d, J = 8.6 Hz, 1H), 6.39 (d, J = 10.1 Hz, 1H), 5.71 (d, 
J = 10.1 Hz, 1H), 4.10 (s, 2H), 3.86 (s, 6H), 2.37 (s, 3H), 1.46 (s, 6H); 13C NMR (75 
MHz, CDCl3) δ 195.4, 168.9,157.1, 148.4, 147.4, 145.6, 131.3, 130.8, 126.7, 121.0, 
115.1, 114.9, 113.1, 112.0, 110.7, 77.0, 55.3, 46.4, 27.8, 20.5; HRESI-MS m/z calcd 
for C23H24O6 397.1646 [M+H]+, found 397.1659. 
 
4.2.17. 
1-(5-(Benzyloxy)-2,2-dimethyl-2H-chromen-6-yl)-2-(3,4-dimethoxyphenyl)-3-phenyl
propan-1-one (16) 
To a solution of compound 9b (100 mg, 0.282 mmol, 1.0 equiv.) in acetonitrile was 
added potassium carbonate (58.4 mg, 0.423 mmol, 1.5 equiv.), and benzyl bromide 
(67 µL, 0.56 mmol, 2.0 equiv.). The mixture was refluxed for 6 h. After the reaction 
was completed, the reaction mixture was treated with 10 mL water and extracted with 
ethyl acetate (3 × 30 mL). The combined organic phases were dried (Na2SO4), and the 
solvent was removed at reduced pressure. The crude residue was purified by column 
chromatography with petroleum/ethyl acetate (6:1) to give 16 as a white solid (120 
mg, 80%).1H NMR (300 MHz, CDCl3) δ 7.40-7.35 (m, 6H), 7.15 (m, 3H), 7.07 (m, 
2H), 6.73 (m, 3H), 6.52 (m, 2H), 5.56 (d, J = 10.1 Hz, 1H), 4.84 (t, J = 7.4 Hz, 1H), 
4.61 (q, J = 11.4 Hz, 2H), 3.81 (s, 3H), 3.72 (s, 3H), 3.51 (m, 1H), 3.01 (m, 1H), 1.39 
(s, 3H), 1.38 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 200.4, 156.6, 153.7, 148.3, 147.4, 
139.6, 136.2, 131.0, 130.4, 130.0, 128.8, 128.0, 127.7, 127.3, 125.5, 125.4, 120.3, 
116.2, 114.8, 112.0, 110.8, 110.6, 77.2, 76.2, 57.8, 55.2, 39.3, 27.6, 27.48; HRESI-MS 
m/z calcd for C35H34O5 [M+H]+ 535.2479, found 535.2511. 
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4.2.18. 1-(2-Hydroxy-4-((2-methylbut-3-yn-2-yl)oxy)phenyl)ethan-1-one (18) 
2,4-Dihydroxyacetophenone (1.0 g, 6.57 mmol, 1.0 equiv.), copper iodide (125 mg, 
0.65 mmol, 0.1 equiv.), potassium iodide (109 mg, 0.65 mmol, 0.1 equiv), 
3-chloro-3-methyl-1-butyne (652.3 µL, 5.92 mmol, 0.9 equiv.), and potassium 
carbonate (1.09 g, 7.89 mmol, 1.2 equiv) was dissolved in 20 mL acetonitrile. The 
mixture was stirred at room temperature for 12 h. After the reaction was completed, 
the solvent was removed at reduced pressure, and the residue was treated with 10 mL 
water and extracted with ethyl acetate (3 × 30 mL). The combined organic phases 
were dried (Na2SO4), and the solvent was removed at reduced pressure. The crude 
residue was purified by column chromatography with petroleum/ethyl acetate (20:1) 
to give 18 as a white solid (0.86 g, 60%). 1H NMR (300 MHz, CDCl3) δ 13.22 (s, 1H), 
7.48 (d, J = 8.9 Hz, 1H), 6.6 (d, J = 8.9 Hz, 1H), 6.53 (s, 1H), 3.61 (s, 1H), 2.63 (s, 
3H), 1.41 (s, 6H); ESI-MS m/z 219.1 [M+H]+. 
 
4.2.19. 1-(5-Hydroxy-2,2-dimethyl-2H-chromen-6-yl)ethan-1-one (19) 
To a solution of N,N-dimethylaniline (5 mL) was added compound 18 (0.858 g), and 
the mixture was heated to 130 °C and stirred for 12 h. After the reaction was 
completed, the solvent was removed at reduced pressure, and the residue was treated 
with 10 mL 10% HCl and extracted with ethyl acetate (3 × 30 mL). The combined 
organic phases were dried (Na2SO4), and the solvent was removed at reduced pressure. 
The crude residue was purified by column chromatography with petroleum/ethyl 
acetate (20:1) to give 19 as a white solid (0.81 g, 95%). 1H NMR (300 MHz, CDCl3) δ 
13.23 (s, 1H), 7.74 (d, J = 8.8 Hz, 1H), 6.94 (d, J = 10.0 Hz, 1H), 6.56 (d, J = 8.8 Hz, 
1H), 5.82 (d, J = 10.0 Hz, 1H), 2.77 (s, 3H), 1.69 (s, 6H); ESI-MS m/z 219.1 [M+H]+. 
 
4.2.20. 1-(5-Methoxy-2,2-dimethyl-2H-chromen-6-yl)ethan-1-one (20) 
Compound 19 (0.81 g, 1.41 mmol, 1.0 equiv.), potassium iodide (61 mg, 0.37 mmol, 
0.1 equiv.), and potassium carbonate (615 mg, 4.45 mmol, 1.2 equiv.) were dissolved 
in 20 mL acetone. The reaction was refluxed for 12 h. After the reaction was 
completed, the solvent was removed at reduced pressure, and the residue was treated 
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with 10 mL water and extracted with ethyl acetate (3 × 30 mL). The combined organic 
phases were dried (Na2SO4), and the solvent was removed at reduced pressure. The 
crude residue was purified by column chromatography with petroleum/ethyl acetate 
(20:1) to give 20 as a white solid (0.60 g, 70%). 1H NMR (300 MHz, CDCl3) δ 7.58 
(d, J = 8.6 Hz, 1H), 6.60 (d, J = 9.8 Hz, 2H), 5.69 (d, J = 10.0 Hz, 1H), 3.80 (s, 3H), 
2.60 (s, 3H), 1.45 (s, 6H); ESI-MS m/z233.1 [M+H]+. 
 
4.2.21. 
2-(3,5-Dimethoxyphenyl)-1-(5-methoxy-2,2-dimethyl-2H-chromen-6-yl)ethan-1-one 
(21a) 
To a solution of 3,5-dimethoxybromobenzene (0.2 g, 0.92 mmol, 1.0 equiv.) in THF 
(20 mL) was added compound 20 (192 mg, 0.82 mmol, 0.9 equiv.), potassium 
tert-butoxide (155 mg, 1.38 mmol, 1.5 equiv.), tris(dibenzylideneacetone)dipalladium 
(0.01 equiv.) and bis(2-diphenylphosphinophenyl)ether (0.01 equiv.). The mixture was 
refluxed for 6 h. After the reaction was completed, the solvent was removed at 
reduced pressure, and the residue was treated with 10 mL water and extracted with 
ethyl acetate (3 × 30 mL). The combined organic phases were dried (Na2SO4), and the 
solvent was removed at reduced pressure. The crude residue was purified by column 
chromatography with petroleum/ethyl acetate (6:1) to give 21a as a pale yellow solid 
(0.24 g, 70%). 1H NMR (300 MHz, CDCl3) δ 7.51 (d, J = 8.6 Hz, 1H), 6.60 (m, 2H), 
6.42 (d, J = 2.1 Hz, 2H), 6.34 (s, 1H), 5.68 (d, J = 10.0 Hz, 1H), 4.20 (s, 2H), 3.76 (s, 
3H), 3.77 (s, 6H), 1.45 (s, 6H); 13C NMR (75 MHz, CDCl3) δ 198.2, 157.3, 155.9, 
148.3, 147.3, 130.7, 130.1, 127.1, 124.3, 121.2, 116.0, 114.3, 112.2, 112.2, 110.6, 76.4, 
62.8, 55.3, 55.9, 47.7, 27.5; HRESI-MS m/z calcd for C22H24O5 369.1697 [M+H]+, 
found 369.1741. 
 
4.2.22. 
2-(2,5-Dimethoxyphenyl)-1-(5-methoxy-2,2-dimethyl-2H-chromen-6-yl)ethan-1-one 
(21b) 
Compound 21b was prepared as the same procedures of 21a with the commercially 
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available 2,5-dimethoxybromobenzene as the starting material. 1H NMR (300 MHz, 
CDCl3) δ 7.58 (d, J = 8.7 Hz, 1H), 6.79 (m, 3H), 6.62 (dd, J = 8.7, 6.1 Hz, 2H), 5.69 
(d, J = 10.0 Hz, 1H), 4.24 (s, 2H), 3.84 (s, 3H), 3.76 (s, 3H), 3.73 (s, 3H), 1.46 (s, 6H); 
13C NMR (75 MHz, CDCl3) δ 197.6, 157.0, 155.9, 152.9, 151.2, 130.6, 129.9, 125.0, 
124.7, 116.9, 116.2, 114.4, 112.0, 111.9, 110.9, 76.3, 62.7, 55.5, 55.2, 43.2, 27.5; 
HRESI-MS m/z calcd for C22H24O5, 369.1697 [M+H]+, found 369.1731. 
 
4.2.23. 
1-(5-Methoxy-2,2-dimethyl-2H-chromen-6-yl)-2-(2,4,5-trimethoxyphenyl)ethan-1-on
e (21c) 
Compound 21c was prepared as the same procedures of 21a with the commercially 
available 2,4,5-trimethoxybromobenzene as the starting material. 1H NMR (300 MHz, 
CDCl3) δ 7.57 (d, J = 8.6 Hz, 1H), 6.74 (s, 1H), 6.68-6.57 (m, 2H), 6.54 (s, 1H), 5.69 
(d, J = 10.0 Hz, 1H), 4.20 (s, 2H), 3.89 (s, 3H), 3.84 (s, 3H), 3.82 (s, 3H), 3.75 (s, 3H), 
1.46 (s, 6H); 13C NMR (75 MHz, CDCl3) δ 198.1, 157.0, 155.8, 151.1, 148.0, 142.3, 
130.5, 130.0, 124.7, 116.2, 115.1, 114.5, 114.4, 112.0, 97.2, 76.2, 62.7, 56.0, 55.9, 
55.6, 42.5, 27.5; HRESI-MS m/z calcd for C23H26O6, 399.1802 [M+H]+, found 
399.1859. 
 
4.2.24. 
1-(5-Methoxy-2,2-dimethyl-2H-chromen-6-yl)-2-(3,4,5-trimethoxyphenyl)ethan-1-on
e (21d) 
Compound 21d was prepared as the same procedures of 21a with the commercially 
available 3,4,5-trimethoxybromobenzene as the starting material. 1H NMR (300 MHz, 
CDCl3) δ 7.58 (d, J = 8.7 Hz, 1H), 6.79 (m, 2H), 6.47 (s, 2H), 5.69 (d, J = 10.0 Hz, 
1H), 4.24 (s, 2H), 3.82 (s, 6H), 3.76 (s, 3H), 3.73 (s, 3H), 1.46 (s, 6H); 13C NMR (75 
MHz, CDCl3) δ 197.8, 157.4, 156.0, 152.6, 136.2, 130.7, 130.2, 130.2, 124.2, 116.0, 
114.4, 112.2, 106.1, 76.4, 62.8, 60.3, 55.5, 48.4, 27.5; HRESI-MS m/z calcd for 
C23H26O6, 399.1802 [M+H]+, found399.1843. 
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4.2.25. 
2-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)-1-(5-methoxy-2,2-dimethyl-2H-chromen-6-
yl)ethan-1-one (21e) 
Compound 21e was prepared as the same procedures of 21a with the commercially 
available 6-bromo-2,3-dihydrobenzo[b][1,4]dioxine as the starting material. 1H NMR 
(300 MHz, CDCl3) δ 7.52 (d, J = 8.7 Hz, 1H), 7.02 (m, 1H), 6.94 (d, J = 8.4 Hz, 1H), 
6.84-6.68 (m, 2H), 6.61 (m, 1H), 5.69 (d, J = 10.0 Hz, 1H), 4.30 (d, J = 7.4 Hz, 2H), 
4.24 (s, 3H), 4.16 (s, 2H), 3.78 (s, 2H), 1.46 (s, 6H); 13C NMR (75 MHz, CDCl3) δ 
198.0, 157.3, 156.0, 142.9, 141.8, 130.7, 130.0, 127.7, 122.1, 117.9, 116.7, 116.1, 
116.0, 114.4, 112.2, 76.4, 63.8, 62.8, 47.3, 27.6; HRESI-MS m/z calcd for C22H22O5 
367.1540 [M+H]+, found 367.1579. 
 
4.2.26. 
1-(5-Methoxy-2,2-dimethylchroman-6-yl)-2-(3,4,5-trimethoxyphenyl)ethan-1-one 
(22) 
To a solution of compound 21d (100 mg) in methanol (10 mL) was added catalytic 
amount of 10% Pd/C. The mixture was reacted under the atmosphere of hydrogen at 
room temperature for 12 h. After the reaction was completed, the mixture was filtrated 
to remove Pd/C and the solvent was removed at reduced pressure to obtained 22 as a 
white solid (95 mg, 95%). 1H NMR (300 MHz, CDCl3) δ 7.47 (d, J = 8.7 Hz, 1H), 
6.55 (d, J = 8.7 Hz, 1H), 6.45 (s, 2H), 4.17 (s, 2H), 3.77 (s, 9H), 3.74 (s, 3H), 2.74 (t, 
J = 6.7 Hz, 2H), 1.76 (t, J = 6.7 Hz, 2H), 1.30 (s, 6H); 13C NMR (75 MHz, CDCl3) δ 
197.9, 158.7, 158.5, 152.5, 136.1, 130.4, 128.9, 123.1, 114.7, 112.9, 106.0, 74.5, 61.3, 
60.2, 55.5, 48.1, 31.4, 26.2, 16.8; HRESI-MS m/z calcd for C23H28O6 401.1959 
[M+H]+, found 401.1981.  
 
4.2.27. 
(E)-3-(3,4-Dimethoxyphenyl)-1-(5-hydroxy-2,2-dimethyl-2H-chromen-6-yl)prop-2-e
n-1-one (23a) 
To a solution of compound 19 (1.0 g, 4.58 mmol, 1.0 equiv.) in anhydrous THF (10 
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mL) was added sodium hydride (164 mg, 6.87 mmol, 1.5 equiv.) at 0 oC. Then 
3,4-dimethoxybenzaldehyde (761.4 mg, 4.58 mmol, 1.0 equiv.) in THF (2 mL) was 
added dropwise. The mixture was slowly warmed up to room temperature and stirred 
for 6 h. After the reaction was completed, the solvent was removed at reduced 
pressure, and the residue was treated with 10 mL water and extracted with ethyl 
acetate (3 × 30 mL). The combined organic phases were dried (Na2SO4), and the 
solvent was removed at reduced pressure. The crude residue was purified by column 
chromatography with petroleum/ethyl acetate (6:1) to give 23a as a red solid (1.18 g, 
70%). 1H NMR (300 MHz, CDCl3) δ 13.74 (s, 1H), 7.84-7.67 (m, 2H), 7.43 (d, J = 
15.4 Hz, 1H), 6.85 (s, 2H), 6.74 (d, J = 10.0 Hz, 1H), 6.38 (d, J = 8.8 Hz, 1H), 5.59 (d, 
J = 10.0 Hz, 1H), 3.92 (s, 6H), 1.47 (s, 6H); 13C NMR (75 MHz, CDCl3) δ 191.2, 
160.4, 159.3, 153.0, 143.9, 140.0, 130.2, 129.8, 127.6, 118.9, 115.3, 113.5, 108.9, 
107.8, 105.2, 77.4, 55.7, 27.9; HRESI-MS m/z calcd for C22H22O5 367.1540 [M+H]+, 
found 367.1567. 
 
4.2.28. 
(E)-1-(5-Hydroxy-2,2-dimethyl-2H-chromen-6-yl)-3-(3,4,5-trimethoxyphenyl)prop-2-
en-1-one (23b) 
Compound 23b was prepared as the same procedures of 23a with the commercially 
available 3,4,5-trimethoxybenzaldehyde as the starting material. 1H NMR (300 MHz, 
CDCl3) δ 13.74 (s, 1H), 7.84-7.67 (m, 2H), 7.43 (d, J = 15.4 Hz, 1H), 6.85 (s, 2H), 
6.74 (d, J = 10.0 Hz, 1H), 6.38 (d, J = 8.8 Hz, 1H), 5.59 (d, J = 10.0 Hz, 1H), 3.92 (s, 
9H), 1.47 (s, 6H); 13C NMR (75 MHz, CDCl3) δ 191.2, 160.4, 159.3, 153.0, 143.9, 
140.0, 130.2, 129.8, 127.6, 118.9, 115.3, 113.5, 108.9, 107.8, 105.2, 77.3, 60.5, 55.7, 
27.9; HRESI-MS m/z calcd for C23H24O6 397.1646 [M+H]+, found 397.1678. 
 
4.3. Cell lines and cell culture 
Human NSCLC cells H1299, A549 and human breast cancer cells HT-29 were 
obtained from the American Type Culture Collection (ATCC, USA). Cells were 
grown in RPMI 1640 medium (Life Technologies, USA). The media for all cell lines 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
32 
 
were supplemented with 10% fetal bovine serum (Life Technologies, USA), 100 
µg/mL streptomycin (Life Technologies, USA), and 100 U/mL penicillin (Life 
Technologies, USA) and maintained at 37°C in a humidified atmosphere with 5% 
CO2. 
 
4.4. Determination of in vitro anticancer activity 
The overall growth of human cancer cell lines was determined using the colorimetric 
MTT assay. Briefly, the cell lines were incubated at 37 °C in a humidified 5 % CO2 
incubator for 24 h in 96-microwell plates prior to the experiments. H1299, MCF-7, 
and A549 cells were seeded at a density of 4,000 cells/well. After the removal of 
medium, 100 µL of fresh medium containing the test compound at different 
concentrations was added to each well and incubated at 37 °C for 72 h. The 
percentage of DMSO in the medium was not exceeded 0.25%. The number of living 
cells after 72 h of culture in the presence (or absence: control) of the various 
compounds is directly proportional to the intensity of the blue, which is quantitatively 
measured by spectrophotometry (Biorad, Nazareth, Belgium) at a 570 nm wavelength. 
The experiment was performed in quadruplicate and repeated three times. 
 
4.5. The fluorescence polarization (FP) competitive binding assay 
In vitro inhibitory activity of compounds on Hsp90 was carried out in 384-well plates 
by fluorescence polarization assay using Hsp90α and Geldanamycin-FITC (Abcam, 
Cambridge, UK) according to the manufacturer's instructions. The assay buffer 
contained 20 mM HEPES pH 7.3, 50 mM KCl, 5 mM MgCl2, 20 mM Na2MoO4, 0.01% 
Triton X-100. Before each use, 100 mg/mL BSA and 2 mM DTT were freshly added. 
In brief, 10 mL of 5 nM FITC-labeled geldanamycin and 10 mL appropriate serials of 
diluted compounds was added to the plate. The reactions were initiated by adding 20 
µL of Hsp90 recombinant enzyme, after 1 h incubation in 4 oC in the dark, the 
fluorescence was measured with excitation wavelength at 485 nm and emission 
wavelength at 535 nm on EnVision Multilabel Reader (Perkin Elmer, Inc.). IC50 were 
calculated using Graphpad Prims 5. (Graphpad Software, Inc). 
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4.6. Wound healing assay 
Cells were seeded on six-well plates with DMEM containing 10% FBS and grown to 
confluence. The cells were scratched with a sterile 200 µL pipette tip to create 
artificial wounds. At 0, 24 and 48 h after wounding, phase-contrast images of the 
wound healing process were photographed digitally using an inverted Olympus IX50 
microscope with 10× objective lens. Eight images per treatment were analyzed to 
determine averaging parameters of positioning of the migrating cells at the wound 
edges by digitally drawing lines using the Image J software. 
 
4.7. Transwell matrix penetration assay 
1× 104 Cells were plated on the top side of the polycarbonate transwell filter with 
matrigel coating in the upper chamber of the BioCoatTM Invasion Chambers (BD, 
Bedford, MA) and incubated at 37 oC for 24 h, followed by removal of cells inside the 
upper chamber with cotton swabs. Invaded cells on the membrane bottom-surface 
were fixed with 1% paraformaldehyde, stained with crystal violet, and counted (Ten 
random 200× fields per well). Cell counts were expressed as the mean number of cells 
per field of view. Three independent experiments were performed. 
 
4.8. Molecular Modelling of 21c in Hsp90 
The crystallographic coordinates of Hsp90 were downloaded from Protein Data Bank 
(PDB ID: 5J2X, 1.22 Å). The structure was edited accordingly by the Protein and 
Ligand Preparation module in Schrodinger and was minimized using the OPLS-2005 
force field. The Glide program was used to study the possible mode of interaction of 
the compounds with Hsp90, The active site was confined in the mass center of 
co-crystal ligand, and the size of bounding box was defined as 10 Å × 10 Å × 10 Å. 
Then compound 21c and deguelin were prepared using the Ligprep module in 
Schrodinger Suite, and were minimized using the OPLS-2005 force field. The 
dockings were performed using the Glide standard precision (Glide-SP) mode with 
the ligands as flexible, the force field was set as OPLS-2005, and all other parameters 
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were set to default. The poses were visualized with PyMOL Molecular Graphics 
System version 2.7.  
 
4.9. Immunoprecipitation 
Immunoprecipitation of Akt experiment was performed according to the 
manufacturer’s instructions. The cells were harvested and lysed by IP lysis buffer (250 
mmol/L HEPES, 50 mmol/L NaCl, 1 mmol/L EDTA, 0.1 mmol/L neocuproine, 1% 
NP-40, Protease Inhibitor Cocktail). Antibodies specific to Hsp90 or Akt (Santa Cruz) 
were added to supernatants followed by an incubation. Immune complexes were then 
precipitated with protein A agarose beads. Bound proteins were eluted by boiling with 
loading buffer and analyzed by Western blotting with anti-Hsp90 or Akt antibodies. 
 
4.10. Hoechst 33258 staining 
Approximately 5×104 cells per well were plated in six-well plates, and the cells were 
then incubated with 0, 0.5, 1.0, 2.0, and 4.0 µM 21c for 36 h. After incubation, cells 
were washed with PBS, fixed in 4% paraformaldehyde for 30 min and then stained 
with 20 µg/ml Hoechst 33258 for 15 min at room temperature in the dark. Cells were 
then assessed by fluorescence microscopy for morphological changes after 21c 
treatment. 
 
4.11. Flow cytometry analysis for cell apoptosis  
MCF-7 cells (1×105/well) were cultured in complete medium in six-well plates for 24 
h and treated in triplicate with different concentrations of 21c for 36 h. The control 
cells were treated with vehicle (1‰ DMSO in complete medium). The cells were 
harvested, washed and stained with propidium iodide (PI), and FITC-Annexin-V in 
the dark for 15 min using the FITC-AnnexinV Kit (BD Parmingen, San Diego, CA, 
USA). The percentages of apoptotic cells were determined by flow cytometry on an 
FC500 cytometer (Beckman Coulter). 
 
4.12. Cell cycle analysis 
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5×104 MCF-7 cells were seeded into six-well plates and incubated overnight. Cells 
were then treated with various concentrations of 21c for 48 h. The cells were 
harvested, washed with cold PBS and then fixed with 70 % ethanol in PBS at -20 °C 
for 12 h. Subsequently, the cells were resuspended in PBS containing 100 µg/mL 
RNase and 50 µg/mL PI and incubated at 37 °C for 30 min. Cell cycle distribution of 
nuclear DNA was determined by flow cytometry on an FC500 cytometer (Beckman 
Coulter). 
 
4.13. Western blot analysis 
MCF-7 cells were incubated with various concentrations of 21c and collected after 48 
h. Cells were centrifuged and washed two times with ice cold phosphate buffered 
saline. The pellet was then resuspended in lysis buffer. After the cells were lysed on 
ice for 20 min, lysates were centrifuged at 13,000 g at 4 °C for 15 min. The protein 
concentration in the supernatant was determined using the BCA protein assay reagents. 
Equal amounts of protein (20 µg) were resolved using sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (8-12 % acrylamide gels) 
and transferred to PVDF Hybond-P membrane. Membranes were blocked for 1 h at 
room temperature. Membranes were then incubated with primary antibodies against 
Bcl-xL, cleaved caspase-3, mTOR, p-mTOR, MAPK, p-MAKP, Akt, p-AKT, HIF-1α, 
Survivin, β-actin, and GAPDH with gentle rotation overnight at 4°C. The bound 
antibodies were detected using horseradish peroxidase (HRP)-conjugated second 
antibodies and visualized by the enhanced chemiluminescent reagent. 
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A series of B- and C-rings truncated deguelin derivatives were designed and 
synthesized. 
Their structure-activity relationships were investigated in a systematic manner. 
Compound 21c was identified to have high Hsp90 binding potency. 
Compound 21c caused apoptosis of MCF-7 cells. 
